A5032787341- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Cancer therapeutics and mechanisms
- Inflammatory Biomarkers in Disease Prognosis
- Immunotherapy and Immune Responses
- Long-Term Effects of COVID-19
- Cancer Diagnosis and Treatment
- Nutrition and Health in Aging
- Immune Cell Function and Interaction
- Esophageal Cancer Research and Treatment
- Diabetes and associated disorders
- Gut microbiota and health
- RNA modifications and cancer
- interferon and immune responses
- Cancer-related molecular mechanisms research
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
Suita Tokushukai Hospital
2019-2025
Kyoto Prefectural University of Medicine
2018-2024
Keio University
2024
Shiga Medical Center
2024
Kyoto University Hospital
2024
Kitasato Institute Hospital
2022
Kitasato University
2022
University Hospital Kyoto Prefectural University of Medicine
2019
Toho University
2006
Abstract Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients EGFR ‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation NSCLC mutations who exhibit clinical outcomes that require treatment immune checkpoint (ICIs). Therefore, identify eligible cases treat ICIs, we retrospectively analyzed correlation between features and efficacy ICIs mutations. Patients Methods...
Secondary sarcopenia is defined as a decrease in muscle mass due to disease or malnutrition. Several studies have reported that secondary an indicator of postoperative recurrence. We hypothesized there correlation between the effect immune checkpoint inhibitors (ICIs) and sarcopenia. retrospectively analyzed 38 patients with advanced non-small cell lung cancer (NSCLC) who were treated ICIs February 2016 April 2018. Patients divided into two groups according change rate psoas major area...
Little is known regarding the effectiveness and tolerability of immune checkpoint inhibitor (ICI) rechallenge after disease progression following initial ICI treatments. To identify eligible patients for rechallenge, we retrospectively analyzed relationship between clinical profiles effect in with non-small cell lung cancer (NSCLC). We enrolled 35 NSCLC at six different institutions who were retreated ICIs discontinued treatments due to progression. Cox proportional hazards models used...
Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated significantly better survival outcomes than alone in patients advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The nutritional index (PNI) (LIPI) biomarkers inhibitor (ICI) monotherapy or chemotherapies. Thus, we aimed to examine whether these factors could also be We retrospectively examined 237 NSCLC treated In...
Programmed cell death protein-1 (PD-1) blockade therapy has improved outcomes in the treatment of advanced cancers. The is well-tolerated, although it occasionally causes immune-related adverse events (irAEs). Thyroid dysfunction one most common irAEs seen. Our aim was to clarify clinical characteristics thyroid induced by PD-1 and its association with therapeutic effect A total 174 patients who received nivolumab or pembrolizumab for metastatic unresectable cancers were included this...
Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of on chemoimmunotherapy unclear. We investigated therapeutic outcomes non-small cell lung (NSCLC). retrospectively analyzed patients' medical records with NSCLC who received in 12 institutions Japan between January and November 2019. defined as weight loss exceeding 5% total body or mass index < 20 kg/m2 more than 2% within 6 months before initiation,...
Reports on the use of cryobiopsy (CB) for lung cancer diagnosis are limited. The aims present study were to evaluate safety and usefulness CB using radial endobronchial ultrasonography, without a guide sheath, peripheral pulmonary lesions determine utility stamp cytology, an on-site diagnostic technique determining tumor inclusion in samples. We retrospectively analyzed data 35 patients (36 lesions) with suspected who underwent between August 2017 February 2019 at our medical facility....
Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Elevated programmed death-ligand 1 (PD-L1) expression in tumors was reported negative predictive outcomes first- or second-generation EGFR-TKIs.We prospectively assessed...
Patients with cancer have been prioritized for vaccination against severe acute respiratory syndrome coronavirus 2. Nevertheless, there are limited data regarding the safety, efficacy, and risk of developing immune-related adverse events (irAEs) associated mRNA vaccines in patients lung cancer, especially those being actively treated immune checkpoint inhibitors. This multicenter observational study was conducted at nine hospitals Japan. (≥20 y) inhibitors between 4 weeks prefirst postsecond...
Although cases of respiratory bacterial infections associated with coronavirus disease 2019 (COVID-19) have often been reported, their impact on the clinical course remains unclear. Herein, we evaluated and analyzed complication rates infections, causative organisms, patient backgrounds, outcome in Japanese patients COVID-19.We performed a retrospective cohort study that included inpatients COVID-19 from multiple centers participating Japan Taskforce (April 2020 to May 2021) obtained...
Abstract Background A history of pre-administration immune checkpoint inhibitors has been reported to be associated with good outcomes ramucirumab (RAM) plus docetaxel (DOC) combination therapy for advanced non-small-cell lung cancer (NSCLC). However, existing knowledge on the clinical significance RAM and DOC following combined chemoimmunotherapy is limited. Therefore, we evaluated efficacy safety after attempted identify predictors its outcomes. Patients Methods This multicenter,...
Abstract Cancer immunotherapy, including atezolizumab monotherapy, is a promising alternative strategy for patients with advanced non-small-cell lung cancer (NSCLC). Several inflammatory indices have been reported as potential biomarkers regarding the effectiveness of various treatments. This study aimed to analyze efficacy monotherapy using baseline markers in NSCLC patients. We retrospectively enrolled 81 who received at six different medical institutions Japan. The Cox proportional...
The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with good clinical outcomes. However, effects remain unknown. In this study, we investigated association between irAEs caused by and efficacy patients NSCLC.We retrospectively analyzed data NSCLC, who received a at six institutions Japan January 2019...
For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, the initial therapeutic interventions will have crucial impacts on their clinical outcomes. Drug tolerant factors reportedly an impact EGFR-tyrosine kinase inhibitor sensitivity. This prospective study investigated of drug tolerant-related protein expression in tumors based efficacy osimertinib first-setting EGFR-mutated advanced NSCLC patients. A total 92 or postoperative recurrent were...
Chemoimmunotherapy improved overall survival (OS) and progression-free (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) two phase III trials. They set the age-stratified subgroup analyses at 65 years; however, over half of were newly diagnosed ≥75 years Japan. Therefore, treatment efficacy safety elderly ≥ 75 ES-SCLC should be evaluated through real-world Japanese evidence. Consecutive untreated or limited-stage SCLC unfit for chemoradiotherapy between 5 August 2019 28...
Importance Immune checkpoint inhibitor (ICI) monotherapy with pembrolizumab and ICI plus chemotherapy have been approved as first-line treatments for non–small cell lung cancer (NSCLC) patients a programmed death ligand–1 (PD-L1) tumor proportion score (TPS) of 50% or more, but the choice between these 2 therapeutic options is unclear. Objective To clarify association history concurrent medication use treatment outcomes ICIs without in NSCLC high PD-L1 TPS to determine whether clinical...
Although osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the incidence of pneumonitis particularly high among Japanese patients receiving drug. Furthermore, safety and efficacy subsequent anticancer treatments, including EGFR-tyrosine kinase inhibitor (TKI) rechallenge, which are to be administered after recovery, remain unclear. This study investigated EGFR-TKI rechallenge in who experienced first-line...